# OnCo record nct06806033 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06806033/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06806033", "NCT06806033" ;
  schema:name "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL"@en ;
  schema:description "A phase 2 trial of Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin in hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06806033/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06806033> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-03-05" ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/> .